CLINICAL TRIALS FOR MULTIPLE MYELOMA
IN CHINA — ACTIVE PROGRAMMES

Three structural features make China genuinely important in the global myeloma trial landscape: First, the volume and pace of cell therapy development. Chinese academic centres and biotechnology companies have been responsible for some of the most influential early-stage and registrational data in BCMA CAR-T (the underlying construct of cilta-cel was first studied in Chinese trials), and they currently lead globally in trial activity for GPRC5D CAR-T, dual-target BCMA-GPRC5D constructs, allogeneic and off-the-shelf platforms, and several novel myeloma antigens. Second, the regulatory pathway. China's NMPA has built an active framework for cell therapy approvals, with two domestically approved BCMA CAR-T products (equecabtagene autoleucel and zevorcabtagene autoleucel) and a clearer route for trial-to-approval transition than in many smaller markets. This means trial-stage products in China today often become approved products within a few years. Third, the cost reality. Trial-based access can substantially reduce the drug component of cell therapy or other novel agent costs, which makes China a meaningful option for international patients without insurance coverage for very expensive Western originator products. Trial enrolment is not free — patients still pay for hospital admission, supportive care, accommodation, and follow-up — but the overall financial commitment is often a fraction of full commercial Western pricing.

BCMA-Directed CAR-T BCMA remains the most established CAR-T target in myeloma. Active Chinese trials cover next-generation autologous BCMA CAR-T platforms with refined binding domains, faster manufacturing, and combination strategies (for example BCMA CAR-T plus immunomodulatory drugs or anti-CD38 antibodies). Some trials also study BCMA CAR-T at earlier lines of therapy, including post-transplant consolidation, where it is being investigated rather than approved. GPRC5D CAR-T GPRC5D-directed CAR-T is one of the most active areas in Chinese myeloma cell therapy research, particularly for patients who have relapsed after BCMA-directed therapy with documented BCMA loss. Trials cover monotherapy GPRC5D CAR-T, dual-target BCMA-GPRC5D constructs, and combination strategies. Chinese centres lead globally in published GPRC5D CAR-T data. Dual-Target BCMA-GPRC5D CAR-T Dual-target constructs aim to reduce antigen escape by recognising both BCMA and GPRC5D simultaneously. Several Chinese trials are using tandem CAR designs, dual CAR co-expression, and cocktail or sequential infusion strategies. These are mostly in heavily pre-treated patients but are increasingly being studied earlier. Allogeneic and Off-the-Shelf CAR-T Allogeneic BCMA CAR-T trials are emerging in Chinese centres for patients whose own T cells are exhausted, where rapid access is needed, or where autologous manufacturing has failed. CAR-NK platforms targeting BCMA, GPRC5D, and CD38 are also in early-phase trials. Novel Antigen CAR-T Beyond BCMA and GPRC5D, Chinese trials are exploring CAR-T against FcRH5, CD38, and other myeloma antigens, often in combination platforms or as alternatives for patients with antigen escape on standard targets. Bispecific Antibodies Trials of T-cell-engaging bispecific antibodies in myeloma cover BCMA, GPRC5D, FcRH5, and other targets. Several international agents (such as teclistamab, elranatamab, talquetamab, and emerging FcRH5 bispecifics) are studied in Chinese-led trials, with separate Chinese-developed bispecifics also in active investigation. Bispecifics offer a non-CAR-T alternative for patients who are not candidates for cell therapy or who relapse after CAR-T. Antibody-Drug Conjugates ADC trials in myeloma cover BCMA-directed and other targets, including next-generation linkers and payloads designed to improve the therapeutic index of older ADC platforms. Small Molecules and Combinations Trials of next-generation immunomodulatory drugs (CELMoDs such as iberdomide and mezigdomide), BCL2 inhibitors (venetoclax-based combinations especially in t(11;14)-positive myeloma), MCL1 inhibitors, and selinexor-based combinations are active in Chinese centres, often in collaboration with international sponsors. Frontline and Maintenance Trials Beyond relapsed disease, Chinese trials cover frontline regimens, post-transplant consolidation, MRD-guided therapy, and maintenance strategies. These are typically less relevant for international travel-for-trial patients but matter for patients already in China.

Eligibility is always reviewed by the trial team and depends on multiple factors:

• Confirmed diagnosis of multiple myeloma with measurable dise

  Confirmed diagnosis of multiple myeloma with measurable disease activity, including paraprotein, free light chains, plasmacytoma, or bone marrow plasma cell percentage above protocol thresholds

• Prior therapy lines matching the protocol's inclusion criter

  Prior therapy lines matching the protocol's inclusion criteria; many cell therapy and bispecific trials require triple-class exposed disease, while others enrol earlier-line patients

• For target-specific trials (BCMA, GPRC5D, FcRH5)

  demonstrable antigen expression on the myeloma cells, confirmed by flow cytometry or IHC

• For post-BCMA trials

  documented prior BCMA-directed therapy and relapse, often with BCMA expression status on relapse biopsy

• Adequate organ function — heart, liver, kidney, lung — with

  Adequate organ function — heart, liver, kidney, lung — with attention to renal function, which is often impaired in myeloma

• Acceptable blood counts and bone marrow reserve for any requ

  Acceptable blood counts and bone marrow reserve for any required lymphodepletion

• ECOG performance status, typically 0 to 2, depending on prot

  ECOG performance status, typically 0 to 2, depending on protocol

• No clinically significant CNS involvement, or treated and st

  No clinically significant CNS involvement, or treated and stable CNS disease in selected protocols

• No active uncontrolled infection, including hepatitis B, hep

  No active uncontrolled infection, including hepatitis B, hepatitis C, or HIV outside protocol allowances

• Sufficient T-cell counts for any cell therapy trial requirin

  Sufficient T-cell counts for any cell therapy trial requiring autologous manufacturing

• Travel fitness and a realistic plan for several weeks of in-

  Travel fitness and a realistic plan for several weeks of in-country care, plus possible bridging therapy during any manufacturing window

• Acceptance of the additional uncertainty inherent in trial-s

  Acceptance of the additional uncertainty inherent in trial-stage therapy compared with approved products

Trial-based treatment costs vary widely. Some Chinese trials provide the investigational product at no cost to the patient, with the family covering hospital, screening, and supportive care. Others operate on a cost-sharing basis or commercial pricing for the investigational product itself. The exact financial structure depends on the sponsor, the centre, and the trial phase. What patients can plan for in most cases: Stay duration depends on the trial type. Cell therapy trials typically require six to ten weeks. Bispecific antibody trials may begin in China and continue with structured follow-up at home after initial step-up dosing. Antibody-drug conjugate and small molecule trials may need shorter initial visits with longer follow-up. CancerFax helps patients understand realistic ranges before travel. Final cost depends on hospital review, the specific trial, and the patient's condition at admission.

• Screening costs, including bone marrow assessment, imaging,

  Screening costs, including bone marrow assessment, imaging, and required laboratory work

• Hospital admission for any required lymphodepletion, infusio

  Hospital admission for any required lymphodepletion, infusion, and monitoring

• Bridging therapy if disease is progressing during screening

  Bridging therapy if disease is progressing during screening or manufacturing windows

• Accommodation, local transport, and interpreter support duri

  Accommodation, local transport, and interpreter support during the in-country stay

• Possible ICU-level care if CRS or other complications are se

  Possible ICU-level care if CRS or other complications are severe

• IVIG replacement and structured follow-up after discharge fo

  IVIG replacement and structured follow-up after discharge for cell therapy trials

• Continuity of follow-up at home, including imaging, lab work

  Continuity of follow-up at home, including imaging, lab work, and disease monitoring

This comparison is general. Many patients receive a combination — an approved CAR-T followed later by a trial-stage GPRC5D platform, or a trial-stage bispecific followed by approved consolidation — rather than choosing one path. The treating haematology team and trial investigators make the final decisions.

Multiple myeloma trials in China are concentrated at major academic and specialist haematology centres in Beijing, Shanghai, Guangzhou, Tianjin, and other cities. Strong trial portfolios operate at the Chinese Academy of Medical Sciences and National Cancer Center, Fudan University Shanghai Cancer Center, Renji Hospital, Ruijin Hospital, Peking University Cancer Hospital, Sun Yat-sen University Cancer Center, Tianjin Medical University Cancer Institute and Hospital, and several university-affiliated haematology and cell therapy units. Trial activity differs between centres. Some are particularly strong in BCMA CAR-T, others in GPRC5D and dual-target constructs, and others in bispecific antibodies or ADC platforms. The right centre for a given case depends on diagnosis, prior therapy, antigen expression, and trial availability rather than hospital reputation alone. CancerFax helps match the case with a centre that fits the clinical situation, not the other way around.

Frequently Asked Questions

Answers to common questions from patients and families.

This guide is for patient education and care navigation support only. It describes general categories of multiple myeloma clinical trials active in Chinese centres. It does not name specific trials, list trial registry numbers, or claim availability of any particular protocol, since trial activity changes continuously based on accrual, sponsor decisions, and regulatory updates. The specific trials open at any given hospital should always be confirmed with the treating team. CancerFax does not sponsor or run clinical trials. The role of CancerFax is to help patients evaluate their case, identify suitable Chinese centres, and connect with trial teams for screening. Enrolment is never guaranteed. Eligibility, treatment choice, response, side effects, cost, and outcomes vary from patient to patient. This page does not replace medical advice from a qualified oncologist or haematologist. CancerFax does not provide emergency medical care. Patients with breathing difficulty, severe bleeding, seizures, sudden weakness, uncontrolled pain, fever during treatment, or rapidly worsening symptoms should contact their treating hospital or emergency services immediately.

Structured reference data summarizing key information for this topic.